PharmaEssentia announced on March 5 that February consolidated revenue reached NT$1.6 billion (+56.65% YoY), marking the second-highest monthly total in the company's history.

• Market Expansion: Its core product, Ropeg (Ropeginterferon alfa-2b), continues to gain momentum in nearly 50 countries for Polycythemia Vera (PV). In Japan, a new "rapid dose escalation" protocol was recently approved, which is expected to accelerate patient response times and drive higher adoption rates.
• Regulatory Milestones: The US FDA has set an action date of August 30, 2026, for Ropeg’s use in Essential Thrombocythemia (ET). Site inspections for the SURPASS-ET and EXCEED-ET trials are currently underway.
• Patient Convenience: PharmaEssentia has submitted data for a pen-injector device to the US FDA, with a commercial launch expected in the second half of 2026. This is anticipated to significantly improve patient compliance and attract a broader long-term user base.

Resource: 藥華藥2月營收16億元、年增逾五成 創單月次高紀錄